Early-Stage Breast Cancer Radiotherapy

Breast Cancer ◽  
2018 ◽  
pp. 445-462
Author(s):  
Kamuran Arslan Ibis ◽  
Makbule Tambas ◽  
Seden Kucucuk
Keyword(s):  
Breast Cancer ◽  
Early Stage ◽  
Early Stage Breast Cancer ◽  
Cancer Radiotherapy ◽  
Breast Cancer Radiotherapy

(P006) Care Pathway Alternatives for Early Stage Breast Cancer Radiotherapy: A National Cancer Database Analysis

2017 ◽  
Vol 98 (2) ◽  
pp. E16-E17
Author(s):  
Ehsan H. Balagamwala ◽  
Bindu V. Manyam ◽  
C.M. Leyrer ◽  
Naveen Karthik ◽  
Timothy Smile ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Stage ◽  
Care Pathway ◽  
Early Stage Breast Cancer ◽  
National Cancer Database ◽  
Database Analysis ◽  
Cancer Radiotherapy ◽  
Breast Cancer Radiotherapy

scholarly journals Advances in Breast Cancer Radiotherapy: Implications for Current and Future Practice

2021 ◽  
Author(s):  
Chirag Shah ◽  
Zahraa Al-Hilli ◽  
Frank Vicini
Keyword(s):  
Breast Cancer ◽  
Early Stage ◽  
Standard Of Care ◽  
Early Stage Breast Cancer ◽  
Partial Breast Irradiation ◽  
Breast Irradiation ◽  
Duration Of Treatment ◽  
Regional Lymph Nodes ◽  
Cancer Radiotherapy ◽  
Breast Cancer Radiotherapy

Radiation therapy (RT) is an essential component in the management of breast cancer. Following breast-conserving surgery (BCS), adjuvant RT is the standard of care for most patients. Traditionally, RT was delivered with standard whole breast irradiation (WBI) over 5-7 weeks following BCS. However, WBI regimens have evolved; hypofractionated WBI now represents the standard approach, reducing the duration of treatment to 3-4 weeks. Over the past year, five-fraction WBI regimens have also emerged as standard of care for some patients based on data from the FAST and FAST-Forward trials. An alternative to WBI that is also available for patients with early-stage breast cancer following BCS is partial breast irradiation, which can reduce the duration of treatment and the volume of breast tissue irradiated. Outcomes from multiple randomized trials with over a 10-year follow-up have demonstrated the safety and efficacy of partial breast irradiation approaches. Single-fraction intraoperative RT has also been evaluated in two prospective trials although the outcomes available, as well as current guidelines, do not support its utilization outside of prospective studies. For patients requiring RT to the regional lymph nodes, data have demonstrated the safety of hypofractionated approaches for those undergoing BCS or mastectomy without reconstruction. Future directions for early-stage breast cancer radiotherapy include the study of even shorter regimens and studies evaluating the omission of RT versus omission of endocrine therapy for favorable-risk patients. Furthermore, studies are also underway evaluating shorter courses of radiation in patients undergoing breast reconstruction and the use of tumor genomics to identify appropriate patients for omission of radiation with limited nodal involvement.

scholarly journals Assessment of Fetal Dose and Health Effect to the Fetus from Breast Cancer Radiotherapy during Pregnancy

Life ◽  
2022 ◽  
Vol 12 (1) ◽  
pp. 84
Author(s):  
Pattarakan Suwanbut ◽  
Thiansin Liamsuwan ◽  
Danupon Nantajit ◽  
Wilai Masa-nga ◽  
Chirapha Tannanonta
Keyword(s):  
Breast Cancer ◽  
Background Radiation ◽  
Early Stage ◽  
Health Effect ◽  
Conformal Radiotherapy ◽  
First Trimester ◽  
Heavy Ion ◽  
Cancer Radiotherapy ◽  
Breast Cancer Radiotherapy ◽  
Fetal Dose

Decision for radiotherapy during the first trimester of pregnancy may occur, as patients may not realize their pregnancy at the very early stage. Since radiation dose can affect fetal development, the aim of this study was to evaluate fetal dose and associated deterministic effects and risks to the fetus from breast cancer radiotherapy of an 8-week pregnant patient. PHITS (Particle and Heavy Ion Transport code System) Monte Carlo simulation and the J-45 computational pregnancy phantom were used to simulate breast cancer radiotherapy from a 6 MV TrueBeam linear accelerator using the three dimensional-conformal radiotherapy (3D-CRT) technique with a prescribed dose to the planning target volume (PTV) of 50 Gy. Once the fetal dose was evaluated, the occurrence of the deterministic effects and risks for developing stochastic effects in the fetus were assessed using the recommendations of NCRP Report No. 174, AAPM Report No. 50, and ICRP Publication 84. The fetal dose was evaluated to be 3.37 ± 2.66 mGy, suggesting that the fetus was expected to have no additional deterministic effects, while the risks for developing cancer and malfunctions were similar to that expected from exposure to background radiation. The comparison with the other studies showed that accurate consideration of fetal position and size was important for dose determination in the fetus, especially at the early pregnancy stage when the fetus is very small.

Mastectomy trends for early-stage breast cancer: a single-center experience

2020 ◽  
Vol 1 (50) ◽  
pp. 9
Author(s):  
Cristian Lungulescu ◽  
Mihaela Dănciulescu ◽  
Denisa Bărbulescu ◽  
Ana Dorobanţu ◽  
Georgiana Camen
Keyword(s):  
Breast Cancer ◽  
Early Stage ◽  
Early Stage Breast Cancer ◽  
Single Center ◽  
Single Center Experience
Sign in / Sign up

Export Citation Format

Share Document